In preclinical studies of CSU, Bexobrutideg demonstrates potent BTK degradation across key immune cell types and enhanced suppression of FcεRI-driven pathology versus remibrutinib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results